MedElevator
Войти в исследования Frontiers in medicine · 2026
Dipyridamole combined with immunoglobulin and aspirin in the treatment of Kawasaki disease in children: a meta-analysis.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shi Yanshuo, Xu Xin, Yue Yuanyuan, Zhao Jianqun, Yao Kaiqing, Wu Huizhen
Аннотация
OBJECTIVE: The objective of this study was to systematically evaluate the clinical efficacy and safety of dipyridamole combined with immunoglobulin and aspirin in the treatment of Kawasaki disease (KD) in children.
METHODS: A computerized search was conducted in databases including PubMed, China Biology Medicine disc (CBM), China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform (Wanfang), and VIP Chinese Sci-Tech Journals Full-text Database (VIP), covering the period from the inception of each database to February 2026. We collected randomized controlled trials (RCTs) that compared the clinical efficacy and safety of dipyridamole combined with immunoglobulin and aspirin (observation group) agains immunoglobulin combined with aspirin (control group) in the treatment of KD in children, in conjunction with standard therapy. After data extraction and quality assessment of clinical studies meeting the inclusion criteria, a meta-analysis was performed using RevMan 5.3 statistical software.
RESULTS: A total of 18 RCTs involving 1,594 patients were included. The meta-analysis results indicated that the total effective rate in the observation group was significantly higher than that in the control group. Additionally, the time for clinical symptom improvement, C-reactive protein levels (CRP), erythrocyte sedimentation rate (ESR), platelet count (PLT), coronary artery lesion (CAL) and fibrinogen levels (FIB) were all significantly lower in the observation group compared to the control group. There was no significant difference in the incidence of adverse reactions between the two groups.
CONCLUSION: The clinical efficacy of dipyridamole combined with immunoglobulin and aspirin in treating Kawasaki disease in children is superior to that of immunoglobulin combined with aspirin, with comparable safety.
SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261336468, identifier CRD420261336468.
METHODS: A computerized search was conducted in databases including PubMed, China Biology Medicine disc (CBM), China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform (Wanfang), and VIP Chinese Sci-Tech Journals Full-text Database (VIP), covering the period from the inception of each database to February 2026. We collected randomized controlled trials (RCTs) that compared the clinical efficacy and safety of dipyridamole combined with immunoglobulin and aspirin (observation group) agains immunoglobulin combined with aspirin (control group) in the treatment of KD in children, in conjunction with standard therapy. After data extraction and quality assessment of clinical studies meeting the inclusion criteria, a meta-analysis was performed using RevMan 5.3 statistical software.
RESULTS: A total of 18 RCTs involving 1,594 patients were included. The meta-analysis results indicated that the total effective rate in the observation group was significantly higher than that in the control group. Additionally, the time for clinical symptom improvement, C-reactive protein levels (CRP), erythrocyte sedimentation rate (ESR), platelet count (PLT), coronary artery lesion (CAL) and fibrinogen levels (FIB) were all significantly lower in the observation group compared to the control group. There was no significant difference in the incidence of adverse reactions between the two groups.
CONCLUSION: The clinical efficacy of dipyridamole combined with immunoglobulin and aspirin in treating Kawasaki disease in children is superior to that of immunoglobulin combined with aspirin, with comparable safety.
SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261336468, identifier CRD420261336468.